{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:13:14Z","timestamp":1793261594041,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS107596-03"],"award-info":[{"award-number":["R01NS107596-03"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin. Auton. Res."],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10286-026-01229-w","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:32:58Z","timestamp":1783042378000},"page":"427-443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular pharmacology of dopaminergic agents in humans: a review"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-6774","authenticated-orcid":false,"given":"Jose-Alberto","family":"Palma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose G.","family":"Gomez Casanovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/dmcn.14613","volume":"62","author":"F Addabbo","year":"2020","unstructured":"Addabbo F, Baglioni V, Schrag A, Schwarz MJ, Dietrich A, Hoekstra PJ, Martino D, Buttiglione M, Emtics Collaborative G (2020) Anti-dopamine D2 receptor antibodies in chronic tic disorders. Dev Med Child Neurol 62:1205\u20131212","journal-title":"Dev Med Child Neurol"},{"key":"1229_CR2","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1172\/JCI118670","volume":"97","author":"FE Albrecht","year":"1996","unstructured":"Albrecht FE, Drago J, Felder RA, Printz MP, Eisner GM, Robillard JE, Sibley DR, Westphal HJ, Jose PA (1996) Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. J Clin Invest 97:2283\u20132288","journal-title":"J Clin Invest"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/mdc3.70004","volume":"12","author":"A Antonini","year":"2025","unstructured":"Antonini A, O\u2019Suilleabhain P, Stocchi F, Landstrom J, Waters S, Sonesson C, Tedroff J (2025) Mesdopetam for the treatment of levodopa induced dyskinesia in Parkinson\u2019s disease: a randomized phase 2b trial. Mov Disord Clin Pract 12:796\u2013806","journal-title":"Mov Disord Clin Pract"},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.physiol.62.1.621","volume":"62","author":"AC Aperia","year":"2000","unstructured":"Aperia AC (2000) Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. Annu Rev Physiol 62:621\u2013647","journal-title":"Annu Rev Physiol"},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.trsl.2014.07.006","volume":"165","author":"I Armando","year":"2015","unstructured":"Armando I, Konkalmatt P, Felder RA, Jose PA (2015) The renal dopaminergic system: novel diagnostic and therapeutic approaches in hypertension and kidney disease. Transl Res 165:505\u2013511","journal-title":"Transl Res"},{"key":"1229_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1172\/JCI3685","volume":"102","author":"LD Asico","year":"1998","unstructured":"Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C, Pocchiari F, Felder RA, Eisner GM, Jose PA (1998) Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest 102:493\u2013498","journal-title":"J Clin Invest"},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3109\/00498254.2010.514961","volume":"40","author":"N Attkins","year":"2010","unstructured":"Attkins N, Betts A, Hepworth D, Heatherington AC (2010) Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. Xenobiotica 40:730\u2013742","journal-title":"Xenobiotica"},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3233\/JPD-171209","volume":"7","author":"S Bacchi","year":"2017","unstructured":"Bacchi S, Chim I, Kramer P, Postuma RB (2017) Domperidone for hypotension in Parkinson\u2019s disease: a systematic review. J Parkinsons Dis 7:603\u2013617","journal-title":"J Parkinsons Dis"},{"key":"1229_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"JM Beaulieu","year":"2011","unstructured":"Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182\u2013217","journal-title":"Pharmacol Rev"},{"key":"1229_CR10","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.amjhyper.2004.07.013","volume":"17","author":"J Beige","year":"2004","unstructured":"Beige J, Bellmann A, Sharma AM, Gessner R (2004) Ethnic origin determines the impact of genetic variants in dopamine receptor gene (DRD1) concerning essential hypertension. Am J Hypertens 17:1184\u20131187","journal-title":"Am J Hypertens"},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/01.HYP.0000198427.96225.36","volume":"47","author":"MJ Bek","year":"2006","unstructured":"Bek MJ, Wang X, Asico LD, Jones JE, Zheng S, Li X, Eisner GM, Grandy DK, Carey RM, Soares-da-Silva P, Jose PA (2006) Angiotensin-II type 1 receptor-mediated hypertension in D4 dopamine receptor-deficient mice. Hypertension 47:288\u2013295","journal-title":"Hypertension"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1016\/S0140-6736(00)03495-4","volume":"356","author":"R Bellomo","year":"2000","unstructured":"Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J (2000) Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356:2139\u20132143","journal-title":"Lancet"},{"key":"1229_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073516","volume":"8","author":"H Ben-Pazi","year":"2013","unstructured":"Ben-Pazi H, Stoner JA, Cunningham MW (2013) Dopamine receptor autoantibodies correlate with symptoms in Sydenham\u2019s chorea. PLoS ONE 8:e73516","journal-title":"PLoS ONE"},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2174\/1871527322666230331121028","volume":"23","author":"E Bezard","year":"2024","unstructured":"Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S (2024) Rationale and development of tavapadon, a D1\/D5-selective partial dopamine agonist for the treatment of Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 23:476\u2013487","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1229_CR15","unstructured":"Biagioni M, Nicholl R, Bornemann T, Legendre C, Leach S, Naik H, el Baghdady A, Williamson N, Benoit A, Menshykau D, Vroye L (2025) Glovadalen, a D1 receptor positive allosteric modulator for people with Parkinson\u2019s who experience significant daily motor fluctuations: a phase II, double-blind, randomized trial. In: International Congress of Parkinson\u2019s Disease and Movement Disorders. Mov Disord, Honolulu, Hawaii, USA"},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/mds.28879","volume":"37","author":"K Biglan","year":"2022","unstructured":"Biglan K, Munsie L, Svensson KA, Ardayfio P, Pugh M, Sims J, Brys M (2022) Safety and efficacy of mevidalen in Lewy body dementia: a phase 2, randomized, placebo-controlled trial. Mov Disord 37:513\u2013524","journal-title":"Mov Disord"},{"key":"1229_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.70039","volume":"15","author":"M Bond","year":"2026","unstructured":"Bond M, Murphy B, Doran B, Darpo B, Xue H, Vrishabhendra L, Isaacsohn J (2026) Results of a phase 1 study assessing the effect of CIN-102, a novel formulation of the dopamine receptor antagonist domperidone designed to treat gastroparesis, on cardiac repolarization in healthy volunteers. Clin Pharmacol Drug Dev 15:e70039","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1229_CR18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/bmj.1.5694.474","volume":"1","author":"DB Calne","year":"1970","unstructured":"Calne DB, Brennan J, Spiers AS, Stern GM (1970) Hypotension caused by L-dopa. Br Med J 1:474\u2013475","journal-title":"Br Med J"},{"key":"1229_CR19","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(69)90536-4","volume":"2","author":"DB Calne","year":"1969","unstructured":"Calne DB, Stern GM, Spiers AS, Laurence DR (1969) L-dopa in idiopathic parkinsonism. Lancet 2:973\u2013976","journal-title":"Lancet"},{"key":"1229_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16061","volume":"31","author":"I Cani","year":"2024","unstructured":"Cani I, Guaraldi P, Giannini G, Sambati L, Barletta G, Cortelli P, Calandra-Buonaura G (2024) Levodopa-induced orthostatic hypotension in parkinsonism: a red flag of autonomic failure. Eur J Neurol 31:e16061","journal-title":"Eur J Neurol"},{"key":"1229_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","volume":"33","author":"F Carbone","year":"2019","unstructured":"Carbone F, Djamshidian A, Seppi K, Poewe W (2019) Apomorphine for Parkinson\u2019s disease: efficacy and safety of current and new formulations. CNS Drugs 33:905\u2013918","journal-title":"CNS Drugs"},{"key":"1229_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/hy0901.096422","volume":"38","author":"RM Carey","year":"2001","unstructured":"Carey RM (2001) Theodore cooper lecture: renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension 38:297\u2013302","journal-title":"Hypertension"},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12991-024-00542-w","volume":"24","author":"CU Correll","year":"2025","unstructured":"Correll CU, Cutler AJ, Laliberte F, Germain G, MacKnight SD, Boudreau J, Wade SW, Nabulsi N, Nguyen HB, Parikh M (2025) Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting. Ann Gen Psychiatry 24:5","journal-title":"Ann Gen Psychiatry"},{"key":"1229_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM196902132800701","volume":"280","author":"GC Cotzias","year":"1969","unstructured":"Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of parkinsonism\u2014chronic treatment with L-dopa. N Engl J Med 280:337\u2013345","journal-title":"N Engl J Med"},{"key":"1229_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00004850-199907000-00002","volume":"14","author":"C Coulouvrat","year":"1999","unstructured":"Coulouvrat C, Dondey-Nouvel L (1999) Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 14:209\u2013218","journal-title":"Int Clin Psychopharmacol"},{"key":"1229_CR26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/jmg.29.12.858","volume":"29","author":"MA Crocq","year":"1992","unstructured":"Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz JC et\u00a0al. (1992) Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 29:858\u2013860","journal-title":"J Med Genet"},{"key":"1229_CR27","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/brain\/aws256","volume":"135","author":"RC Dale","year":"2012","unstructured":"Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, Ben-Pazi H, Varadkar S, Aumann TD, Horne MK, Church AJ, Fath T, Brilot F (2012) Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 135:3453\u20133468","journal-title":"Brain"},{"key":"1229_CR28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41386-020-00908-0","volume":"46","author":"A Desai","year":"2021","unstructured":"Desai A, Benner L, Wu R, Gertsik L, Maruff P, Light GA, Uz T, Marek GJ, Zhu T (2021) Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D(1) receptor positive allosteric modulator in patients with schizophrenia. Neuropsychopharmacology 46:1145\u20131151","journal-title":"Neuropsychopharmacology"},{"key":"1229_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40262-020-00911-0","volume":"60","author":"A Desai","year":"2021","unstructured":"Desai A, Benner L, Wu R, Gertsik L, Uz T, Marek GJ, Zhu T (2021) Pharmacokinetics of ASP4345 from single ascending-dose and multiple ascending-dose Phase I studies. Clin Pharmacokinet 60:79\u201388","journal-title":"Clin Pharmacokinet"},{"key":"1229_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1212\/WNL.40.4.707","volume":"40","author":"G Durrieu","year":"1990","unstructured":"Durrieu G, Senard JM, Rascol O, Tran MA, Lataste X, Rascol A, Montastruc JL (1990) Blood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208\u2013243). Neurology 40:707\u2013709","journal-title":"Neurology"},{"key":"1229_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/00002826-199102000-00007","volume":"14","author":"G Durrieu","year":"1991","unstructured":"Durrieu G, Senard JM, Tran MA, Rascol A, Montastruc JL (1991) Effects of levodopa and bromocriptine on blood pressure and plasma catecholamines in parkinsonians. Clin Neuropharmacol 14:84\u201390","journal-title":"Clin Neuropharmacol"},{"key":"1229_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10286-024-01024-5","volume":"34","author":"T Earl","year":"2024","unstructured":"Earl T, Jridi A, Thulin PC, Zorn M, McKee KE, Mitrovich K, Moretti P, Alshaikh J, Kassavetis P, Cortez MM, Lamotte G (2024) Effect of levodopa on postural blood pressure changes in Parkinson disease: a randomized crossover study. Clin Auton Res 34:117\u2013124","journal-title":"Clin Auton Res"},{"key":"1229_CR33","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1210\/jcem.82.11.4339","volume":"82","author":"G Eisenhofer","year":"1997","unstructured":"Eisenhofer G, Aneman A, Friberg P, Hooper D, Fandriks L, Lonroth H, Hunyady B, Mezey E (1997) Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 82:3864\u20133871","journal-title":"J Clin Endocrinol Metab"},{"key":"1229_CR34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/jamaneurol.2026.0577","volume":"83","author":"HH Fernandez","year":"2026","unstructured":"Fernandez HH, Isaacson SH, Hauser RA, Agarwal P, Ondo W, Park A, Kremens D, Leoni M, Duvvuri S, Combs C, Koenig E, Chang I, Pastino G, Tringali S, Golonski N, Sanchez R, Harmer L, Boiser J, Zadikoff C, Mari Z (2026) Tavapadon as adjunctive treatment for Parkinson disease: the TEMPO-3 randomized clinical trial. JAMA Neurol 83:442\u2013451","journal-title":"JAMA Neurol"},{"key":"1229_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.2165\/00003495-199039020-00009","volume":"39","author":"A Fitton","year":"1990","unstructured":"Fitton A, Benfield P (1990) Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. Drugs 39:308\u2013330","journal-title":"Drugs"},{"key":"1229_CR36","unstructured":"Food and Drug Administration (2004) APOKYN prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021264s025lbl.pdf"},{"key":"1229_CR37","unstructured":"Food and Drug Administration (2004) ONAPGO prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214056s000lbl.pdf"},{"key":"1229_CR38","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40263-019-00646-y","volume":"33","author":"JE Frampton","year":"2019","unstructured":"Frampton JE (2019) Rotigotine transdermal patch: a review in Parkinson\u2019s disease. CNS Drugs 33:707\u2013718","journal-title":"CNS Drugs"},{"key":"1229_CR39","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-059574","author":"DL Gilbert","year":"2023","unstructured":"Gilbert DL, Dubow JS, Cunniff TM, Wanaski SP, Atkinson SD, Mahableshwarkar AR (2023) Ecopipam for tourette syndrome: a randomized trial. Pediatrics. https:\/\/doi.org\/10.1542\/peds.2022-059574","journal-title":"Pediatrics"},{"key":"1229_CR40","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/mdc3.70091","volume":"12","author":"DL Gilbert","year":"2025","unstructured":"Gilbert DL, Kim DJB, Miller MM, Atkinson SD, Karkanias GB, Munschauer FE, Wanaski SP, Cunniff TM (2025) Safety and effect of 12-month ecopipam treatment in pediatric patients with Tourette syndrome. Mov Disord Clin Pract 12:1157\u20131166","journal-title":"Mov Disord Clin Pract"},{"key":"1229_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ajmg.b.30273","volume":"141B","author":"SJ Glatt","year":"2006","unstructured":"Glatt SJ, Jonsson EG (2006) The Cys allele of the DRD2 Ser311Cys polymorphism has a dominant effect on risk for schizophrenia: evidence from fixed- and random-effects meta-analyses. Am J Med Genet B Neuropsychiatr Genet 141B:149\u2013154","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1229_CR42","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1161\/01.HYP.0000188052.69549.e4","volume":"46","author":"DS Goldstein","year":"2005","unstructured":"Goldstein DS, Eldadah BA, Holmes C, Pechnik S, Moak J, Saleem A, Sharabi Y (2005) Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 46:1333\u20131339","journal-title":"Hypertension"},{"key":"1229_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1365-2125.1976.tb04877.x","volume":"3","author":"JK Greenacre","year":"1976","unstructured":"Greenacre JK, Teychenne PF, Petrie A, Calne DB, Leigh PN, Reid JL (1976) The cardiovascular effects of bromocriptine in Parkinsonism. Br J Clin Pharmacol 3:571\u2013574","journal-title":"Br J Clin Pharmacol"},{"key":"1229_CR44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2165\/11591710-000000000-00000","volume":"25","author":"JJ Gugger","year":"2011","unstructured":"Gugger JJ (2011) Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs 25:659\u2013671","journal-title":"CNS Drugs"},{"key":"1229_CR45","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40261-018-0632-6","volume":"38","author":"R Gurrell","year":"2018","unstructured":"Gurrell R, Duvvuri S, Sun P, DeMartinis N (2018) A phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel dopamine D1 receptor partial agonist, PF-06669571, in subjects with idiopathic Parkinson\u2019s disease. Clin Drug Investig 38:509\u2013517","journal-title":"Clin Drug Investig"},{"key":"1229_CR46","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s002130100725","volume":"155","author":"M Haney","year":"2001","unstructured":"Haney M, Ward AS, Foltin RW, Fischman MW (2001) Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology 155:330\u2013337","journal-title":"Psychopharmacology"},{"key":"1229_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/00003495-198836010-00003","volume":"36","author":"JM Henwood","year":"1988","unstructured":"Henwood JM, Todd PA (1988) Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 36:11\u201331","journal-title":"Drugs"},{"key":"1229_CR48","doi-asserted-by":"publisher","first-page":"10801","DOI":"10.1523\/JNEUROSCI.22-24-10801.2002","volume":"22","author":"TR Hollon","year":"2002","unstructured":"Hollon TR, Bek MJ, Lachowicz JE, Ariano MA, Mezey E, Ramachandran R, Wersinger SR, Soares-da-Silva P, Liu ZF, Grinberg A, Drago J, Young WS 3rd, Westphal H, Jose PA, Sibley DR (2002) Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. J Neurosci: Off J Soc Neurosci 22:10801\u201310810","journal-title":"J Neurosci: Off J Soc Neurosci"},{"key":"1229_CR49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/01.RES.10.2.237","volume":"10","author":"D Horwitz","year":"1962","unstructured":"Horwitz D, Fox Sm D, Goldberg LI (1962) Effects of dopamine in man. Circ Res 10:237\u2013243","journal-title":"Circ Res"},{"key":"1229_CR50","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3233\/JPD-202188","volume":"10","author":"X Huang","year":"2020","unstructured":"Huang X, Lewis MM, Van Scoy LJ, De Jesus S, Eslinger PJ, Arnold AC, Miller AJ, Fernandez-Mendoza J, Snyder B, Harrington W, Kong L, Wang X, Sun D, Delnomdedieu M, Duvvuri S, Mahoney SE, Gray DL, Mailman RB (2020) The D1\/D5 dopamine partial agonist PF-06412562 in advanced-stage Parkinson\u2019s disease: a feasibility study. J Parkinsons Dis 10:1515\u20131527","journal-title":"J Parkinsons Dis"},{"key":"1229_CR51","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/00005344-198407000-00005","volume":"6","author":"DW Johns","year":"1984","unstructured":"Johns DW, Ayers CR, Carey RM (1984) The dopamine agonist bromocriptine induces hypotension by venous and arteriolar dilation. J Cardiovasc Pharmacol 6:582\u2013587","journal-title":"J Cardiovasc Pharmacol"},{"key":"1229_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074116","volume":"8","author":"TL Johnson","year":"2013","unstructured":"Johnson TL, Tulis DA, Keeler BE, Virag JA, Lust RM, Clemens S (2013) The dopamine D3 receptor knockout mouse mimics aging-related changes in autonomic function and cardiac fibrosis. PLoS ONE 8:e74116","journal-title":"PLoS ONE"},{"key":"1229_CR53","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A (2018) Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749\u2013759","journal-title":"Lancet Neurol"},{"key":"1229_CR54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMra1509723","volume":"382","author":"H Kaufmann","year":"2020","unstructured":"Kaufmann H, Norcliffe-Kaufmann L, Palma JA (2020) Baroreflex dysfunction. N Engl J Med 382:163\u2013178","journal-title":"N Engl J Med"},{"key":"1229_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10667-5","author":"Christopher Koch","year":"2026","unstructured":"Koch C, Khalid S, Khan MZ, Bandyadka S, Doyon B, Denning DP, Jahanzaib M,br \/Mian MR, Gul W, Liaqat MB, Bano A, DaharM, Saqib N, Kamani L, Butt N, Jalal A,br \/Sultana R, Abbas S, Siddiqeh M, Haroon M, Khan A, Babar KP, Rasheed A, Iqbal J,br\/Aslam F, Usman U, Bajwa MA, Hyder A, Memon MS, Hashmani N, Haroon MI, Muddassirbr \/A, Zaidi SAR, Akram M, HussainM, Mohsin SN, Bugti S, Mehmood T, Rodeni AL,br \/Mukhtar S, Rasool T, Mahmood A, Wazir MN, Khan SJ, Khan MA, Ghaffar R,Jan S, Ulbr \/Hadi N, Anjum R, Abdullah R, Musharraf MU, Bashir MT, Ali M, Majeed I, Bilal MH,br \/Khan SA, Hata C, Kou I,Asaumi M, Morii W, Smith KR, Kundu K, Lythgow K,br \/MacArthur S, Wasilewski S, Petrovski S; Regeneron Genetics Center;Rodriguez-br \/Flores JL, Riaz M, Kapoor M, Backman JD, Shuldiner AR, Bradner JE, Splawski I, Rasheed A, Dominy JE, GurtanAM, Saleheen D (2026) Analysis of 173,303 exomes and genomes in the Pakistan Genome Resource. Nature. https:\/\/doi.org\/10.1038\/s41586-026-10667-5","journal-title":"Nature"},{"key":"1229_CR56","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/hmg\/7.9.1379","volume":"7","author":"J Krushkal","year":"1998","unstructured":"Krushkal J, Xiong M, Ferrell R, Sing CF, Turner ST, Boerwinkle E (1998) Linkage and association of adrenergic and dopamine receptor genes in the distal portion of the long arm of chromosome 5 with systolic blood pressure variation. Hum Mol Genet 7:1379\u20131383","journal-title":"Hum Mol Genet"},{"key":"1229_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00005344-198907000-00010","volume":"14","author":"J Kubota","year":"1989","unstructured":"Kubota J, Kubo S, Nishimura H, Ueyama M, Kino M, Nakayama A, Hara M, Kawamura K (1989) Cardiorenal effects of an orally active dopamine prodrug (TA-870) in patients with congestive heart failure. J Cardiovasc Pharmacol 14:53\u201357","journal-title":"J Cardiovasc Pharmacol"},{"key":"1229_CR58","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1001\/archneur.57.10.1461","volume":"57","author":"K Kujawa","year":"2000","unstructured":"Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG (2000) Acute orthostatic hypotension when starting dopamine agonists in Parkinson\u2019s disease. Arch Neurol 57:1461\u20131463","journal-title":"Arch Neurol"},{"key":"1229_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/11319860-000000000-00000","volume":"33","author":"J Kulisevsky","year":"2010","unstructured":"Kulisevsky J, Pagonabarraga J (2010) Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson\u2019s disease: meta-analysis of randomized controlled trials. Drug Saf 33:147\u2013161","journal-title":"Drug Saf"},{"key":"1229_CR60","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1161\/01.CIR.78.5.1310","volume":"78","author":"NA Lass","year":"1988","unstructured":"Lass NA, Glock D, Goldberg LI (1988) Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine. Circulation 78:1310\u20131315","journal-title":"Circulation"},{"key":"1229_CR61","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/01.HYP.38.3.303","volume":"38","author":"XX Li","year":"2001","unstructured":"Li XX, Bek M, Asico LD, Yang Z, Grandy DK, Goldstein DS, Rubinstein M, Eisner GM, Jose PA (2001) Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice. Hypertension 38:303\u2013308","journal-title":"Hypertension"},{"key":"1229_CR62","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/00002826-199619050-00005","volume":"19","author":"ME Llau","year":"1996","unstructured":"Llau ME, Durrieu G, Tran MA, Senard JM, Rascol O, Montastruc JL (1996) A study of dopaminergic sensitivity in Parkinson\u2019s disease: comparison in \u201cde novo\u201d and levodopa-treated patients. Clin Neuropharmacol 19:420\u2013427","journal-title":"Clin Neuropharmacol"},{"key":"1229_CR63","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/phar.70066","volume":"45","author":"K Longardner","year":"2025","unstructured":"Longardner K, Liu C, Momper J, Mahato K, Moonla C, Ghodsi H, Wang J, Litvan I (2025) Acute pharmacodynamic effects of oral levodopa on blood pressure in Parkinson\u2019s disease. Pharmacotherapy 45:721\u2013728","journal-title":"Pharmacotherapy"},{"key":"1229_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/j.1552-4604.1992.tb03788.x","volume":"32","author":"A Luchsinger","year":"1992","unstructured":"Luchsinger A, Velasco M, Urbina A, Morillo J, Romero E, Alvarez R, Pieretti OH (1992) Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients. J Clin Pharmacol 32:55\u201360","journal-title":"J Clin Pharmacol"},{"key":"1229_CR65","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1056\/NEJM196612222752501","volume":"275","author":"KL MacCannell","year":"1966","unstructured":"MacCannell KL, McNay JL, Meyer MB, Goldberg LI (1966) Dopamine in the treatment of hypotension and shock. N Engl J Med 275:1389\u20131398","journal-title":"N Engl J Med"},{"key":"1229_CR66","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1017\/S1092852900002273","volume":"9","author":"S Madhusoodanan","year":"2004","unstructured":"Madhusoodanan S, Brenner R, Gupta S, Reddy H, Bogunovic O (2004) Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr 9:862\u2013867","journal-title":"CNS Spectr"},{"key":"1229_CR67","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(73)92729-3","volume":"2","author":"CD Marsden","year":"1973","unstructured":"Marsden CD, Parkes JD, Rees JE (1973) A year\u2019s comparison of treatment of patients with Parkinson\u2019s disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 2:1459\u20131462","journal-title":"Lancet"},{"key":"1229_CR68","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1055\/s-2007-1013173","volume":"47","author":"K Matsubayashi","year":"1999","unstructured":"Matsubayashi K, Ueda Y, Ogino H, Sugita T, Sakakibara Y, Matsuyama K, Nomoto T (1999) Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery. Thorac Cardiovasc Surg 47:352\u2013356","journal-title":"Thorac Cardiovasc Surg"},{"key":"1229_CR69","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/mds.28634","volume":"36","author":"NE Mencacci","year":"2021","unstructured":"Mencacci NE, Steel D, Magrinelli F, Hsu J, Keller Sarmiento IJ, Troncoso Schifferli M, Munoz D, Stefanis L, Lubbe SJ, Wood NW, Kurian MA, Stamelou M (2021) Childhood-onset chorea caused by a recurrent de novo DRD2 variant. Mov Disord 36:1472\u20131473","journal-title":"Mov Disord"},{"key":"1229_CR70","doi-asserted-by":"publisher","first-page":"e164762","DOI":"10.1172\/jci.insight.164762","volume":"9","author":"CM Menendez","year":"2024","unstructured":"Menendez CM, Zuccolo J, Swedo SE, Reim S, Richmand B, Ben-Pazi H, Kovoor A, Cunningham MW (2024) Dopamine receptor autoantibody signaling in infectious sequelae differentiates movement versus neuropsychiatric disorders. JCI Insight 9:e164762","journal-title":"JCI Insight"},{"key":"1229_CR71","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/BF01819541","volume":"2","author":"M Merello","year":"1992","unstructured":"Merello M, Pirtosek Z, Bishop S, Lees AJ (1992) Cardiovascular reflexes in Parkinson\u2019s disease: effect of domperidone and apomorphine. Clin Auton Res 2:215\u2013219","journal-title":"Clin Auton Res"},{"key":"1229_CR72","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"C Missale","year":"1998","unstructured":"Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189\u2013225","journal-title":"Physiol Rev"},{"key":"1229_CR73","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.drudis.2011.12.020","volume":"17","author":"P Morgan","year":"2012","unstructured":"Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD (2012) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today 17:419\u2013424","journal-title":"Drug Discov Today"},{"key":"1229_CR74","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1056\/NEJMra010253","volume":"345","author":"MB Murphy","year":"2001","unstructured":"Murphy MB, Murray C, Shorten GD (2001) Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345:1548\u20131557","journal-title":"N Engl J Med"},{"key":"1229_CR75","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/08919887211060017","volume":"35","author":"D Nimmons","year":"2022","unstructured":"Nimmons D, Bhanu C, Orlu M, Schrag A, Walters K (2022) Orthostatic hypotension and antiparkinsonian drugs: a systematic review and meta-analysis. J Geriatr Psychiatry Neurol 35:639\u2013654","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1229_CR76","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1527-3466.1992.tb00239.x","volume":"10","author":"S Nishiyama","year":"1992","unstructured":"Nishiyama S, Yoshikawa M, Yamaguchi I (1992) An orally effective peripheral dopamine prodrug: docarpamine (TA\u2010870). Cardiovasc Drug Rev 10:101\u2013116","journal-title":"Cardiovasc Drug Rev"},{"key":"1229_CR77","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2165\/11536840-000000000-00000","volume":"33","author":"C van Noord","year":"2010","unstructured":"van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC (2010) Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 33:1003\u20131014","journal-title":"Drug Saf"},{"key":"1229_CR78","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1093\/hmg\/3.12.2207","volume":"3","author":"MM Nothen","year":"1994","unstructured":"Nothen MM, Cichon S, Hemmer S, Hebebrand J, Remschmidt H, Lehmkuhl G, Poustka F, Schmidt M, Catalano M, Fimmers R et\u00a0al. (1994) Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet 3:2207\u20132212","journal-title":"Hum Mol Genet"},{"key":"1229_CR79","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000489574","volume":"79","author":"H Oka","year":"2018","unstructured":"Oka H, Nakahara A, Umehara T (2018) Rotigotine improves abnormal circadian rhythm of blood pressure in Parkinson\u2019s disease. Eur Neurol 79:281\u2013286","journal-title":"Eur Neurol"},{"key":"1229_CR80","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1161\/01.HYP.30.3.725","volume":"30","author":"R Ozono","year":"1997","unstructured":"Ozono R, O\u2019Connell DP, Wang ZQ, Moore AF, Sanada H, Felder RA, Carey RM (1997) Localization of the dopamine D1 receptor protein in the human heart and kidney. Hypertension 30:725\u2013729","journal-title":"Hypertension"},{"key":"1229_CR81","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1001\/jamaneurol.2026.0590","volume":"83","author":"R Pahwa","year":"2026","unstructured":"Pahwa R, Moro E, Espay AJ, Evans A, Saint-Hilaire M, Torres-Russotto D, Sanchez R, Leoni M, Duvvuri S, Combs C, Chang I, Tringali S, Boiser J, Zadikoff C, Antonini A (2026) Fixed-dose Tavapadon for early Parkinson disease: a randomized clinical trial. JAMA Neurol 83:452\u2013460","journal-title":"JAMA Neurol"},{"key":"1229_CR82","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","volume":"68","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, Investigators E-PAS (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68:1108\u20131115","journal-title":"Neurology"},{"key":"1229_CR83","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10286-024-01016-5","volume":"34","author":"JA Palma","year":"2024","unstructured":"Palma JA (2024) Muscarinic control of cardiovascular function in humans: a review of current clinical evidence. Clin Auton Res 34:31\u201344","journal-title":"Clin Auton Res"},{"key":"1229_CR84","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.parkreldis.2020.04.011","volume":"75","author":"JA Palma","year":"2020","unstructured":"Palma JA, Redel-Traub G, Porciuncula A, Samaniego-Toro D, Millar Vernetti P, Lui YW, Norcliffe-Kaufmann L, Kaufmann H (2020) The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension. Parkinsonism Relat Disord 75:97\u2013104","journal-title":"Parkinsonism Relat Disord"},{"key":"1229_CR85","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41575-025-01112-5","volume":"22","author":"TS Pasricha","year":"2025","unstructured":"Pasricha TS, Kulkarni S (2025) Dopaminergic signalling in gastrointestinal health and disease. Nat Rev Gastroenterol Hepatol 22:696\u2013707","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1229_CR86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/mds.870050315","volume":"5","author":"W Poewe","year":"1990","unstructured":"Poewe W, Luef G, Kleedorfer B, Emre M (1990) Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205\u2013502, in patients with fluctuating Parkinson\u2019s disease. Mov Disord 5:257\u2013259","journal-title":"Mov Disord"},{"key":"1229_CR87","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/WNL.0b013e31822affb0","volume":"77","author":"W Poewe","year":"2011","unstructured":"Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH, Pramipexole ERSG (2011) Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 77:759\u2013766","journal-title":"Neurology"},{"key":"1229_CR88","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/jnnp.44.5.426","volume":"44","author":"N Quinn","year":"1981","unstructured":"Quinn N, Illas A, Lhermitte F, Agid Y (1981) Bromocriptine in Parkinson\u2019s disease: a study of cardiovascular effects. J Neurol Neurosurg Psychiatry 44:426\u2013429","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1229_CR89","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1046\/j.1365-2680.1998.1820115.x","volume":"18","author":"A Ricci","year":"1998","unstructured":"Ricci A, Bronzetti E, Fedele F, Ferrante F, Zaccheo D, Amenta F (1998) Pharmacological characterization and autoradiographic localization of a putative dopamine D4 receptor in the heart. J Auton Pharmacol 18:115\u2013121","journal-title":"J Auton Pharmacol"},{"key":"1229_CR90","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1056\/NEJM198606053142307","volume":"314","author":"D Robertson","year":"1986","unstructured":"Robertson D, Goldberg MR, Onrot J, Hollister AS, Wiley R, Thompson JG Jr, Robertson RM (1986) Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine. N Engl J Med 314:1494\u20131497","journal-title":"N Engl J Med"},{"key":"1229_CR91","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000339000","volume":"68","author":"C Rocchi","year":"2012","unstructured":"Rocchi C, Pierantozzi M, Pisani V, Marfia GA, Di Giorgio A, Stanzione P, Bernardi G, Stefani A (2012) The impact of rotigotine on cardiovascular autonomic function in early Parkinson\u2019s disease. Eur Neurol 68:187\u2013192","journal-title":"Eur Neurol"},{"key":"1229_CR92","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/157488610791698334","volume":"5","author":"M Rossi","year":"2010","unstructured":"Rossi M, Giorgi G (2010) Domperidone and long QT syndrome. Curr Drug Saf 5:257\u2013262","journal-title":"Curr Drug Saf"},{"key":"1229_CR93","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","volume":"53","author":"A Di Sarno","year":"2000","unstructured":"Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53:53\u201360","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1229_CR94","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/01.HYP.36.2.183","volume":"36","author":"M Sato","year":"2000","unstructured":"Sato M, Soma M, Nakayama T, Kanmatsuse K (2000) Dopamine D1 receptor gene polymorphism is associated with essential hypertension. Hypertension 36:183\u2013186","journal-title":"Hypertension"},{"key":"1229_CR95","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70587","volume":"19","author":"VD Schmith","year":"2026","unstructured":"Schmith VD, English S, Dymond A, Holdsworth C, Stow R, Holbrook E, Schleyer J, Wanaski SP (2026) Ecopipam, a dopamine D1 receptor antagonist: pharmacokinetics, mass balance, and metabolism in healthy volunteers. Clin Transl Sci 19:e70587","journal-title":"Clin Transl Sci"},{"key":"1229_CR96","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1161\/01.HYP.25.5.1075","volume":"25","author":"HP Schobel","year":"1995","unstructured":"Schobel HP, Schmieder RE, Hartmann S, Schachinger H, Luft FC (1995) Effects of bromocriptine on cardiovascular regulation in healthy humans. Hypertension 25:1075\u20131082","journal-title":"Hypertension"},{"key":"1229_CR97","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s40478-016-0397-1","volume":"4","author":"N Sinmaz","year":"2016","unstructured":"Sinmaz N, Tea F, Pilli D, Zou A, Amatoury M, Nguyen T, Merheb V, Ramanathan S, Cooper ST, Dale RC, Brilot F (2016) Dopamine-2 receptor extracellular N-terminus regulates receptor surface availability and is the target of human pathogenic antibodies from children with movement and psychiatric disorders. Acta Neuropathol Commun 4:126","journal-title":"Acta Neuropathol Commun"},{"key":"1229_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.792","volume":"9","author":"F Sjoberg","year":"2021","unstructured":"Sjoberg F, Waters S, Lofberg B, Sonesson C, Waters N, Tedroff J (2021) A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers. Pharmacol Res Perspect 9:e00792","journal-title":"Pharmacol Res Perspect"},{"key":"1229_CR99","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40120-018-0114-z","volume":"7","author":"US Sohur","year":"2018","unstructured":"Sohur US, Gray DL, Duvvuri S, Zhang Y, Thayer K, Feng G (2018) Phase 1 Parkinson\u2019s disease studies show the dopamine D1\/D5 agonist PF-06649751 is safe and well tolerated. Neurol Ther 7:307\u2013319","journal-title":"Neurol Ther"},{"key":"1229_CR100","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/HYPERTENSIONAHA.107.109611","volume":"51","author":"JA Staessen","year":"2008","unstructured":"Staessen JA, Kuznetsova T, Zhang H, Maillard M, Bochud M, Hasenkamp S, Westerkamp J, Richart T, Thijs L, Li X, Brand-Herrmann SM, Burnier M, Brand E (2008) Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4. Hypertension 51:1643\u20131650","journal-title":"Hypertension"},{"key":"1229_CR101","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/bcp.13128","volume":"83","author":"J Taubel","year":"2017","unstructured":"Taubel J, Ferber G, Fox G, Fernandes S, Lorch U, Camm AJ (2017) Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. Br J Clin Pharmacol 83:339\u2013348","journal-title":"Br J Clin Pharmacol"},{"key":"1229_CR102","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1553-2712.2000.tb02039.x","volume":"7","author":"JA Tumlin","year":"2000","unstructured":"Tumlin JA, Dunbar LM, Oparil S, Buckalew V, Ram CV, Mathur V, Ellis D, McGuire D, Fellmann J, Luther RR (2000) Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial fenoldopam study group. Acad Emerg Med 7:653\u2013662","journal-title":"Acad Emerg Med"},{"key":"1229_CR103","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0895-7061(03)01013-6","volume":"16","author":"A Ueda","year":"2003","unstructured":"Ueda A, Ozono R, Oshima T, Yano A, Kambe M, Teranishi Y, Katsuki M, Chayama K (2003) Disruption of the type 2 dopamine receptor gene causes a sodium-dependent increase in blood pressure in mice. Am J Hypertens 16:853\u2013858","journal-title":"Am J Hypertens"},{"key":"1229_CR104","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Ponten F (2015) Proteomics. Tissue-based map of the human proteome. Science 347:1260419","journal-title":"Science"},{"key":"1229_CR105","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00045391-199801000-00007","volume":"5","author":"M Velasco","year":"1998","unstructured":"Velasco M, Luchsinger A (1998) Dopamine: pharmacologic and therapeutic aspects. Am J Ther 5:37\u201343","journal-title":"Am J Ther"},{"key":"1229_CR106","first-page":"S475","volume-title":"International Congress of Parkinson\u2019s Disease and Movement Disorders","author":"C Vermeiren","year":"2022","unstructured":"Vermeiren C, Ates A, Bouzom F, Delaunois A, Gillard M, Kenda B, Ousset A, Provins L, Skolc D, Valade A (2022) Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM). International Congress of Parkinson\u2019s Disease and Movement Disorders. Mov Disord, Madrid, pp. S475\u2013S475"},{"key":"1229_CR107","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00467-008-0901-3","volume":"23","author":"X Wang","year":"2008","unstructured":"Wang X, Villar VA, Armando I, Eisner GM, Felder RA, Jose PA (2008) Dopamine, kidney, and hypertension: studies in dopamine receptor knockout mice. Pediatr Nephrol 23:2131\u20132146","journal-title":"Pediatr Nephrol"},{"key":"1229_CR108","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/mds.28385","volume":"36","author":"MCM van der Weijden","year":"2021","unstructured":"van der Weijden MCM, Rodriguez-Contreras D, Delnooz CCS, Robinson BG, Condon AF, Kielhold ML, Stormezand GN, Ma KY, Dufke C, Williams JT, Neve KA, Tijssen MAJ, Verbeek DS (2021) A gain-of-function variant in dopamine D2 receptor and progressive chorea and dystonia phenotype. Mov Disord 36:729\u2013739","journal-title":"Mov Disord"},{"key":"1229_CR109","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/cpdd.874","volume":"10","author":"D Wilbraham","year":"2021","unstructured":"Wilbraham D, Biglan KM, Svensson KA, Tsai M, Kielbasa W (2021) Safety, tolerability, and pharmacokinetics of mevidale (LY3154207), a centrally acting dopamine D1 receptor-positive allosteric modulator (D1PAM), in healthy subjects. Clinical Pharmacol Drug Dev 10:393\u2013403","journal-title":"Clinical Pharmacol Drug Dev"},{"key":"1229_CR110","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/bph.12988","volume":"172","author":"M Wood","year":"2015","unstructured":"Wood M, Dubois V, Scheller D, Gillard M (2015) Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol 172:1124\u20131135","journal-title":"Br J Pharmacol"},{"key":"1229_CR111","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","volume":"21","author":"MD Yahr","year":"1969","unstructured":"Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM (1969) Treatment of Parkinsonism with levodopa. Arch Neurol 21:343\u2013354","journal-title":"Arch Neurol"},{"key":"1229_CR112","doi-asserted-by":"publisher","first-page":"H551","DOI":"10.1152\/ajpheart.01036.2007","volume":"294","author":"C Zeng","year":"2008","unstructured":"Zeng C, Armando I, Luo Y, Eisner GM, Felder RA, Jose PA (2008) Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice. Am J Physiol Heart Circ Physiol 294:H551-569","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1229_CR113","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/mds.10359","volume":"18","author":"M Ziegler","year":"2003","unstructured":"Ziegler M, Castro-Caldas A, Del Signore S, Rascol O (2003) Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson\u2019s disease: a 6-month, randomized, placebo-controlled study. Mov Disord 18:418\u2013425","journal-title":"Mov Disord"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-026-01229-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10286-026-01229-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-026-01229-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:02:58Z","timestamp":1786460578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10286-026-01229-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s10286-026-01229-w","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.A.P.: research support from the National Institute of Health (NIH)-National Institute of Neurological Disorders and Stroke (NINDS), royalties from UpToDate, and salary\u00a0support from Eli Lilly. Eli Lilly is the developer of mevidalen (mentioned in this article); Eli Lilly was not involved in the conception or writing of this manuscript. JGGC: nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}